{"protocolSection":{"identificationModule":{"nctId":"NCT00501826","orgStudyIdInfo":{"id":"2006-0328"},"secondaryIdInfos":[{"id":"NCI-2012-01518","type":"REGISTRY","domain":"CTRP (Clinical Trial Reporting Program)"},{"id":"2006-0328","type":"OTHER","domain":"M D Anderson Cancer Center"}],"organization":{"fullName":"M.D. Anderson Cancer Center","class":"OTHER"},"briefTitle":"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","officialTitle":"Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma"},"statusModule":{"statusVerifiedDate":"2024-08","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-07-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-10-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-10-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2007-07-12","studyFirstSubmitQcDate":"2007-07-13","studyFirstPostDateStruct":{"date":"2007-07-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-08-26","lastUpdatePostDateStruct":{"date":"2024-08-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"M.D. Anderson Cancer Center","class":"OTHER"},"collaborators":[{"name":"National Cancer Institute (NCI)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.","detailedDescription":"PRIMARY OBJECTIVES:\n\nI. To determine the complete remission (CR) rate and progression-free survival following treatment with hyperfractionated cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (hyper-CVAD) in combination with nelarabine in previously untreated patients with T-cell acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma.\n\nII. To determine the safety and overall survival of previously untreated patients with T-cell ALL and T-cell lymphoblastic lymphoma.\n\nIII. To determine the safety and efficacy of adding pegaspargase to the regimen.\n\nIV. To determine the safety and efficacy of adding venetoclax to the regimen.\n\nOUTLINE:\n\nCOURSES 1, 3, 5, and 7 (hyper-CVAD): Patients receive cyclophosphamide intravenously (IV) over 3 hours twice daily (BID) on day 1-3, doxorubicin IV over 24 hours on day 4, vincristine IV over 15-30 minutes on days 4 and 11, and dexamethasone IV or orally (PO) once daily (QD) on days 1-4 and 11-14.\n\nCOURSES 2, 4, 6, and 8 (methotrexate/cytarabine): Patients receive methotrexate IV over 24 hours on day 1 and cytarabine IV over 2 hours BID on days 2 and 3.\n\nPatients also receive venetoclax PO QD on days 1-14 of each course. Courses of hyper-CVAD and methotrexate/cytarabine repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nPatients also receive nelarabine IV over 2 hours once daily (QD) for 5 days and pegaspargase IV over 2 hours on day 5 after completion of course 4 and after the completion of course 5 in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE COURSES 1-5, 8-17, and 20-30 (mercaptopurine, vincristine, methotrexate, and prednisone \\[POMP\\]): Patients receive mercaptopurine PO thrice daily (TID), methotrexate PO once weekly, vincristine sulfate IV on day 1, prednisone PO QD on days 1-5, and venetoclax PO QD on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nINTENSIFICATION COURSES 6 and 7: Patients receive nelarabine IV QD over 2 hours on days 1-5 and pegaspargase IV over 2 hours on day 5. Patients also receive venetoclax PO QD on days 1-14. Courses repeat every 21-35 days in the absence of disease progression or unacceptable toxicity.\n\nINTENSIFICATION COURSES 18 and 19: Patients receive methotrexate IV over 2 hours on day 1, pegaspargase IV over 2 hours on day 2, and venetoclax PO QD on days 1-14 in the absence of disease progression or unacceptable toxicity.\n\nPOMP maintenance therapy continues for 30 months in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed up every 3-6 months."},"conditionsModule":{"conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":160,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment (nelarabine and combination chemotherapy)","type":"EXPERIMENTAL","description":"See Detailed Description","interventionNames":["Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Nelarabine","Drug: Pegaspargase","Drug: Prednisone","Drug: Venetoclax","Drug: Vincristine Sulfate"]}],"interventions":[{"type":"DRUG","name":"Cyclophosphamide","description":"Given IV","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"type":"DRUG","name":"Cytarabine","description":"Given IV","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":[".beta.-Cytosine arabinoside","1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-.beta.-D-Arabinofuranosylcytosine","1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-Beta-D-arabinofuranosylcytosine","1.beta.-D-Arabinofuranosylcytosine","2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-","Alexan","Ara-C","ARA-cell","Arabine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-cytosine Arabinoside","CHX-3311","Cytarabinum","Cytarbel","Cytosar","Cytosine Arabinoside","Cytosine-.beta.-arabinoside","Cytosine-beta-arabinoside","Erpalfa","Starasid","Tarabine PFS","U 19920","U-19920","Udicil","WR-28453"]},{"type":"DRUG","name":"Dexamethasone","description":"Given IV or PO","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycadron","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decadron DP","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasone Intensol","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Fluorodelta","Fortecortin","Gammacorten","Hexadecadrol","Hexadrol","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","TaperDex","Visumetazone","ZoDex"]},{"type":"DRUG","name":"Doxorubicin Hydrochloride","description":"Given IV","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin HCl","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","hydroxydaunorubicin","Rubex"]},{"type":"DRUG","name":"Mercaptopurine","description":"Given PO","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":["3H-Purine-6-thiol","6 MP","6 Thiohypoxanthine","6 Thiopurine","6-Mercaptopurine","6-Mercaptopurine Monohydrate","6-MP","6-Purinethiol","6-Thiopurine","6-Thioxopurine","6H-Purine-6-thione, 1,7-dihydro- (9CI)","7-Mercapto-1,3,4,6-tetrazaindene","Alti-Mercaptopurine","Azathiopurine","BW 57-323H","Flocofil","Ismipur","Leukerin","Leupurin","Mercaleukim","Mercaleukin","Mercaptina","Mercaptopurinum","Mercapurin","Mern","NCI-C04886","Puri-Nethol","Purimethol","Purine, 6-mercapto-","Purine-6-thiol (8CI)","Purine-6-thiol, monohydrate","Purinethiol","Purinethol","U-4748","WR-2785"]},{"type":"DRUG","name":"Methotrexate","description":"Given IV and PO","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]},{"type":"DRUG","name":"Nelarabine","description":"Given IV","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":["2-Amino-6-methoxypurine arabinoside","506U78","Arranon","Compound 506U78","GW506U78"]},{"type":"DRUG","name":"Pegaspargase","description":"Given IV","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":["L-Asparaginase with Polyethylene Glycol","Oncaspar","Oncaspar-IV","PEG-Asparaginase","PEG-L-Asparaginase","PEG-L-Asparaginase (Enzon - Kyowa Hakko)","PEGLA","Polyethylene Glycol L-Asparaginase","Polyethylene Glycol-L-Asparaginase"]},{"type":"DRUG","name":"Prednisone","description":"Given PO","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":[".delta.1-Cortisone","1, 2-Dehydrocortisone","Adasone","Cortancyl","Dacortin","DeCortin","Decortisyl","Decorton","Delta 1-Cortisone","Delta-Dome","Deltacortene","Deltacortisone","Deltadehydrocortisone","Deltasone","Deltison","Deltra","Econosone","Lisacort","Meprosona-F","Metacortandracin","Meticorten","Ofisolona","Orasone","Panafcort","Panasol-S","Paracort","Perrigo Prednisone","PRED","Predicor","Predicorten","Prednicen-M","Prednicort","Prednidib","Prednilonga","Predniment","Prednisone Intensol","Prednisonum","Prednitone","Promifen","Rayos","Servisone","SK-Prednisone"]},{"type":"DRUG","name":"Venetoclax","description":"Given PO","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":["ABT-0199","ABT-199","ABT199","GDC-0199","RG7601","Venclexta","Venclyxto"]},{"type":"DRUG","name":"Vincristine Sulfate","description":"Given IV","armGroupLabels":["Treatment (nelarabine and combination chemotherapy)"],"otherNames":["Kyocristine","Leurocristine sulfate","Leurocristine, sulfate","Oncovin","Vincasar","Vincosid","Vincrex","Vincristine, sulfate"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Complete remission rate","description":"The sample size will provide an estimate of relapse rate at 3 years with a 95% confidence interval of width +/- 10%.","timeFrame":"3 years"},{"measure":"Duration of remission","description":"Duration of remission will be evaluated.","timeFrame":"Up to 9 years"},{"measure":"Progression-free survival","description":"Progression-free survival will be estimated.","timeFrame":"3 years"},{"measure":"Overall survival","description":"Overall survival will be estimated.","timeFrame":"3 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Previously untreated T cell ALL including T cell lymphoblastic lymphoma; failure to one induction course of chemotherapy are eligible; patients in CR after =\\< 2 courses are also eligible\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3\n* Serum bilirubin less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 5.0 mg/dL is acceptable\n* Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) less than or equal to 4 x upper limit of normal (ULN)\n* Serum creatinine less than or equal to 2.0 mg/dL unless considered due to involvement by tumor when an upper limit of 2.5 mg/dL is acceptable\n\nExclusion Criteria:\n\n* Pregnant or nursing women","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Farhad Ravandi-Kashani, MD","role":"CONTACT","phone":"713-745-0394"}],"overallOfficials":[{"name":"Farhad Ravandi-Kashani","affiliation":"M.D. Anderson Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"M D Anderson Cancer Center","status":"RECRUITING","city":"Houston","state":"Texas","zip":"77030","country":"United States","contacts":[{"name":"Farhad Ravandi-Kashani","role":"CONTACT","phone":"713-745-0394"},{"name":"Farhad Ravandi-Kashani","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"referencesModule":{"seeAlsoLinks":[{"label":"MD Anderson Cancer Center","url":"http://www.mdanderson.org"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-08-28"},"conditionBrowseModule":{"meshes":[{"id":"D000008223","term":"Lymphoma"},{"id":"D000007938","term":"Leukemia"},{"id":"D000054198","term":"Precursor Cell Lymphoblastic Leukemia-Lymphoma"},{"id":"D000007945","term":"Leukemia, Lymphoid"},{"id":"D000008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D000054218","term":"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"}],"ancestors":[{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000008232","term":"Lymphoproliferative Disorders"},{"id":"D000008206","term":"Lymphatic Diseases"},{"id":"D000007160","term":"Immunoproliferative Disorders"},{"id":"D000007154","term":"Immune System Diseases"},{"id":"D000006402","term":"Hematologic Diseases"}],"browseLeaves":[{"id":"M11220","name":"Lymphoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"M10945","name":"Leukemia","asFound":"Leukemia","relevance":"HIGH"},{"id":"M27585","name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","asFound":"Lymphoblastic lymphoma","relevance":"HIGH"},{"id":"M10951","name":"Leukemia, Lymphoid","asFound":"Lymphoblastic Leukemia","relevance":"HIGH"},{"id":"M27587","name":"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","asFound":"T Acute Lymphoblastic Leukemia","relevance":"HIGH"},{"id":"M18120","name":"Leukemia-Lymphoma, Adult T-Cell","relevance":"LOW"},{"id":"M11222","name":"Lymphoma, Non-Hodgkin","asFound":"Lymphoblastic lymphoma","relevance":"HIGH"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M11225","name":"Lymphoproliferative Disorders","relevance":"LOW"},{"id":"M11203","name":"Lymphatic Diseases","relevance":"LOW"},{"id":"M10206","name":"Immunoproliferative Disorders","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"M9490","name":"Hematologic Diseases","relevance":"LOW"},{"id":"T3543","name":"Lymphosarcoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"T175","name":"Acute Lymphoblastic Leukemia","asFound":"Acute Lymphoblastic Leukemia","relevance":"HIGH"},{"id":"T3533","name":"Lymphoblastic Lymphoma","asFound":"Lymphoblastic lymphoma","relevance":"HIGH"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"},{"id":"T224","name":"Adult T-cell Leukemia/lymphoma","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000003561","term":"Cytarabine"},{"id":"C000069956","term":"6-methoxypurine arabinoside"},{"id":"D000003907","term":"Dexamethasone"},{"id":"C000018038","term":"Dexamethasone acetate"},{"id":"D000011241","term":"Prednisone"},{"id":"D000003348","term":"Cortisone"},{"id":"D000003520","term":"Cyclophosphamide"},{"id":"D000004317","term":"Doxorubicin"},{"id":"C000506643","term":"Liposomal doxorubicin"},{"id":"D000008727","term":"Methotrexate"},{"id":"D000014750","term":"Vincristine"},{"id":"C000579720","term":"Venetoclax"},{"id":"D000001215","term":"Asparaginase"},{"id":"D000015122","term":"Mercaptopurine"},{"id":"C000042705","term":"Pegaspargase"},{"id":"C000101468","term":"BB 1101"}],"ancestors":[{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000018906","term":"Antineoplastic Agents, Alkylating"},{"id":"D000000477","term":"Alkylating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000019653","term":"Myeloablative Agonists"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000000932","term":"Antiemetics"},{"id":"D000001337","term":"Autonomic Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000005765","term":"Gastrointestinal Agents"},{"id":"D000005938","term":"Glucocorticoids"},{"id":"D000006728","term":"Hormones"},{"id":"D000006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"},{"id":"D000018931","term":"Antineoplastic Agents, Hormonal"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000000903","term":"Antibiotics, Antineoplastic"},{"id":"D000059005","term":"Topoisomerase II Inhibitors"},{"id":"D000059003","term":"Topoisomerase Inhibitors"},{"id":"D000000020","term":"Abortifacient Agents, Nonsteroidal"},{"id":"D000000019","term":"Abortifacient Agents"},{"id":"D000012102","term":"Reproductive Control Agents"},{"id":"D000000964","term":"Antimetabolites, Antineoplastic"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000003879","term":"Dermatologic Agents"},{"id":"D000005493","term":"Folic Acid Antagonists"},{"id":"D000019384","term":"Nucleic Acid Synthesis Inhibitors"},{"id":"D000000998","term":"Antiviral Agents"},{"id":"D000000890","term":"Anti-Infective Agents"},{"id":"D000000972","term":"Antineoplastic Agents, Phytogenic"},{"id":"D000050257","term":"Tubulin Modulators"},{"id":"D000050256","term":"Antimitotic Agents"},{"id":"D000050258","term":"Mitosis Modulators"}],"browseLeaves":[{"id":"M7102","name":"Dexamethasone","asFound":"High","relevance":"HIGH"},{"id":"M11703","name":"Methotrexate","asFound":"Under","relevance":"HIGH"},{"id":"M235549","name":"Dexamethasone acetate","asFound":"MTD","relevance":"HIGH"},{"id":"M199152","name":"BB 1101","asFound":"MTD","relevance":"HIGH"},{"id":"M6727","name":"Cyclophosphamide","asFound":"Tablet","relevance":"HIGH"},{"id":"M249656","name":"Venetoclax","asFound":"ER","relevance":"HIGH"},{"id":"M14121","name":"Prednisone","asFound":"Min","relevance":"HIGH"},{"id":"M7492","name":"Doxorubicin","asFound":"Muscle","relevance":"HIGH"},{"id":"M17495","name":"Vincristine","asFound":"Salt","relevance":"HIGH"},{"id":"M6766","name":"Cytarabine","asFound":"Dysfunction","relevance":"HIGH"},{"id":"M251156","name":"Pegaspargase","asFound":"Amlodipine 5 mg","relevance":"HIGH"},{"id":"M17853","name":"Mercaptopurine","asFound":"Supportive","relevance":"HIGH"},{"id":"M227339","name":"Liposomal doxorubicin","asFound":"Muscle","relevance":"HIGH"},{"id":"M6569","name":"Cortisone","asFound":"Radial","relevance":"HIGH"},{"id":"M4522","name":"Asparaginase","asFound":"Place","relevance":"HIGH"},{"id":"M340456","name":"6-methoxypurine arabinoside","asFound":"Activation Syndrome","relevance":"HIGH"},{"id":"M256061","name":"Ichthammol","relevance":"LOW"},{"id":"M10212","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M10201","name":"Immunologic Factors","relevance":"LOW"},{"id":"M20604","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M20942","name":"Antineoplastic Agents, Alkylating","relevance":"LOW"},{"id":"M3820","name":"Alkylating Agents","relevance":"LOW"},{"id":"M4217","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M4251","name":"Antiemetics","relevance":"LOW"},{"id":"M8881","name":"Gastrointestinal Agents","relevance":"LOW"},{"id":"M9047","name":"Glucocorticoids","relevance":"LOW"},{"id":"M9789","name":"Hormones","relevance":"LOW"},{"id":"M9788","name":"Hormone Antagonists","relevance":"LOW"},{"id":"M20966","name":"Antineoplastic Agents, Hormonal","relevance":"LOW"},{"id":"M19609","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M14343","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M4222","name":"Anti-Bacterial Agents","relevance":"LOW"},{"id":"M4224","name":"Antibiotics, Antitubercular","relevance":"LOW"},{"id":"M29348","name":"Topoisomerase Inhibitors","relevance":"LOW"},{"id":"M4281","name":"Antimetabolites","relevance":"LOW"},{"id":"M7074","name":"Dermatologic Agents","relevance":"LOW"},{"id":"M17546","name":"Vitamin B Complex","relevance":"LOW"},{"id":"M8618","name":"Folic Acid","relevance":"LOW"},{"id":"M8619","name":"Folic Acid Antagonists","relevance":"LOW"},{"id":"M4314","name":"Antiviral Agents","relevance":"LOW"},{"id":"M4214","name":"Anti-Infective Agents","relevance":"LOW"},{"id":"M26197","name":"Tubulin Modulators","relevance":"LOW"},{"id":"M26196","name":"Antimitotic Agents","relevance":"LOW"},{"id":"T447","name":"Folinic Acid","relevance":"LOW"},{"id":"T446","name":"Folic Acid","relevance":"LOW"},{"id":"T448","name":"Folate","relevance":"LOW"},{"id":"T475","name":"Vitamin B9","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"AnEm","name":"Antiemetics"},{"abbrev":"Gast","name":"Gastrointestinal Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"Derm","name":"Dermatologic Agents"},{"abbrev":"Repr","name":"Reproductive Control Agents"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Hemat","name":"Hematinics"},{"abbrev":"Vi","name":"Vitamins"}]}},"hasResults":false}